Exabis Library
Welcome to the e-CCO Library!
P553 Safety of the sequential use of biological therapy in inflammatory bowel disease: Results from a tertiary referral centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P553: Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P553: Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P553: Factors related to steroid consumption in IBD patients: Evidence from a multicenter Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P553: Long-term outcomes of seton drainage for perianal fistulizing Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P554 Dietary practices and beliefs of patients with inactive ulcerative colitis: A prospective UK study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P554: Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P554: Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P554: Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P554: Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P554: Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P554: Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P555 Frequent disease relapse after withdrawal of infliximab in IBD patients with sustained remission
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P555: Coagulation disorders in a population of patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P555: Deep remission and mucosal healing in IBD patients under immunosuppression with azathioprine and 6-mercaptopurine
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P555: Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P555: Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P555: Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM